共查询到15条相似文献,搜索用时 156 毫秒
1.
2.
3.
从实体瘤脱落进入血液循环系统的肿瘤细胞即循环肿瘤细胞(CTCs)与肿瘤转移密切相关,因此CTCs检测对癌症患者的诊断、治疗监测、病情评估以及肿瘤转移机制研究具有重要意义。由于CTCs在体内含量极少、异质性、分布不均一,通过体外采血发展的CTCs检测技术虽然已取得很大进展,但仍然面临肿瘤细胞损失、失活、失真以及灵敏度低等问题,因此亟需发展基于体内快速流动血液的肿瘤细胞检测技术,在真实生理状态下实时监测CTCs动态变化。在此,我们总结了CTCs体内检测技术及其相关应用的研究进展,分析了这些技术的优势和不足。最后,讨论并展望了CTCs体内检测技术的未来发展趋势。 相似文献
4.
循环肿瘤细胞(CTCs)出现于癌症患者的外周血中,是一种重要的游离态组织样本,对于癌症的早期诊断和预后评估具有非常重要的临床诊断价值。由于血液中CTCs含量极少,对其进行分选富集是CTCs检测和分析的一个重要预处理步骤。传统的宏观方法虽然也能实现细胞分离,但存在耗时长、样品需求量大、目标细胞损失严重及硬件设备依赖性高等不足。近年来兴起的微流控技术可在微米尺度范围内集成物理、化学及生物手段,易于实现整体器件的微型化和低成本便携式发展,为稀有CTCs的高灵敏度、高效分选提供重要的潜在技术手段。本文综述了微流控技术实现CTCs分选的最新研究进展,详细阐述了各种被动、主动分选方法的原理及成功应用实例,分析各方法的优缺点,提出一种新型的多级分选芯片结构,并最后探讨了微流控CTCs分选芯片在临床应用中面临的挑战及未来的发展趋势。 相似文献
5.
6.
癌症作为常见病正严重威胁着我国乃至全球居民的健康。循环肿瘤细胞(CTCs)是一类由癌变部位释放并进入血液中的癌细胞,其在癌症的早期诊断、个体化及肿瘤转移机制研究等方面的作用正逐渐被发现和认可,但由于血液中的CTCs含量极少,对其分选极具挑战。微流控芯片作为一种微型化、高通量、集成化平台,在CTCs研究中彰显了独特的优势,相关报道也越来越多。随着研究的深入,微流控芯片技术不再局限于基于模型样品的方法学开发,而是更注重于能否用于临床实际样品中CTCs的检测,但目前未见该角度的综述报道。为此,文章综述了近年来用于临床实际样品CTCs分析的微流控芯片分选技术,并探讨了微流控芯片用于CTCs分选的发展趋势。 相似文献
7.
纳米生物无机界面的研究是无机化学学科新兴的前沿领域之一。纳米结构的无机材料在仿生界面、细胞界面、生物检测界面等领域扮演着越来越重要的角色。近几年来,无机纳米结构被尝试用于痕量循环肿瘤细胞(Circulating Tumor Cells,CTCs)分离的基础探索研究中,并展现出非常吸引人的应用前景。痕量CTCs的高效分离对于癌症早期检测、术后监测及生物学研究等具有重要的意义。本文主要综述纳米生物无机界面在CTCs分离中的应用,详细介绍其发展现状,并对未来做一展望。 相似文献
8.
纳米生物无机界面的研究是无机化学学科新兴的前沿领域之一。纳米结构的无机材料在仿生界面、细胞界面、生物检测界面等领域扮演着越来越重要的角色。近几年来, 无机纳米结构被尝试用于痕量循环肿瘤细胞(Circulating Tumor Cells, CTCs)分离的基础探索研究中, 并展现出非常吸引人的应用前景。痕量CTCs的高效分离对于癌症早期检测、术后监测及生物学研究等具有重要的意义。本文主要综述纳米生物无机界面在CTCs分离中的应用, 详细介绍其发展现状, 并对未来做一展望。 相似文献
9.
癌症的精准诊疗是提高癌症患者生存率和生存质量的重要手段.液体活检通过采用非侵入采样方式,获取肿瘤病人全面、准确、实时的基因组、转录组及蛋白组等生物学信息,是一种新兴的癌症诊断技术,对癌症精确诊断、个体化治疗、预后评估等方面具有重要意义.循环肿瘤细胞(CTC)是一种从实体瘤组织脱落进入外周血的肿瘤细胞,因能提供完整的细胞生物学信息,是最具应用前景的液体活检靶标.然而, CTC的数量极其稀少、异质性强、所处外周血环境复杂等特点,给CTC的富集和分析带来了巨大的技术挑战.本文将总结本课题组近年来发展的基于CTC液体活检策略,着重讨论在CTC识别、富集与单细胞分析等方面的研究进展. 相似文献
10.
11.
《Angewandte Chemie (Weinheim an der Bergstrasse, Germany)》2017,129(36):10821-10825
Even though the diagnostic and prognostic value of circulating tumor cells (CTCs) has been demonstrated, their clinical utility and widespread adoption have been limited. Herein, we describe a new device, size‐dictated immunocapture chip (SDI‐Chip), for efficient, sensitive, and spatially resolved capture and detection of CTCs. SDI‐Chip enables selective, frequent, and extended interaction of CTCs with hydrodynamically optimized immunocoated micropillar surfaces. CTCs with different antigen expression levels can be efficiently captured and spatially resolved around the micropillars. Capture efficiency greater than 92 % with a purity of 82 % was achieved with blood samples. CTCs were detected in non‐metastasis colorectal (CRC) patients, while none was detected from healthy volunteers. We believe that SDI‐Chip will facilitate the transition of tumor diagnosis from anatomical pathology to molecular pathology in localized CRC patients. 相似文献
12.
《Angewandte Chemie (International ed. in English)》2017,56(36):10681-10685
Even though the diagnostic and prognostic value of circulating tumor cells (CTCs) has been demonstrated, their clinical utility and widespread adoption have been limited. Herein, we describe a new device, size‐dictated immunocapture chip (SDI‐Chip), for efficient, sensitive, and spatially resolved capture and detection of CTCs. SDI‐Chip enables selective, frequent, and extended interaction of CTCs with hydrodynamically optimized immunocoated micropillar surfaces. CTCs with different antigen expression levels can be efficiently captured and spatially resolved around the micropillars. Capture efficiency greater than 92 % with a purity of 82 % was achieved with blood samples. CTCs were detected in non‐metastasis colorectal (CRC) patients, while none was detected from healthy volunteers. We believe that SDI‐Chip will facilitate the transition of tumor diagnosis from anatomical pathology to molecular pathology in localized CRC patients. 相似文献
13.
Nanoparticle‐Mediated Binning and Profiling of Heterogeneous Circulating Tumor Cell Subpopulations 下载免费PDF全文
Dr. Reza M. Mohamadi Justin D. Besant Adam Mepham Brenda Green Dr. Laili Mahmoudian Thaddeus Gibbs Dr. Ivaylo Ivanov Anahita Malvea Jessica Stojcic Alison L. Allan Lori E. Lowes Prof. Edward H. Sargent Robert K. Nam Prof. Shana O. Kelley 《Angewandte Chemie (International ed. in English)》2015,54(1):139-143
The analysis of circulating tumor cells (CTCs) is an important capability that may lead to new approaches for cancer management. CTC capture devices developed to date isolate a bulk population of CTCs and do not differentiate subpopulations that may have varying phenotypes with different levels of clinical relevance. Here, we present a new device for CTC spatial sorting and profiling that sequesters blood‐borne tumor cells with different phenotypes into discrete spatial bins. Validation data are presented showing that cancer cell lines with varying surface expression generate different binning profiles within the device. Working with patient blood samples, we obtain profiles that elucidate the heterogeneity of CTC populations present in cancer patients and also report on the status of CTCs within the epithelial‐to‐mesenchymal transition (EMT). 相似文献
14.
Bichsel CA Gobaa S Kobel S Secondini C Thalmann GN Cecchini MG Lutolf MP 《Lab on a chip》2012,12(13):2313-2316
Microfluidic technology has been successfully applied to isolate very rare tumor-derived epithelial cells (circulating tumor cells, CTCs) from blood with relatively high yield and purity, opening up exciting prospects for early detection of cancer. However, a major limitation of state-of-the-art CTC-chips is their inability to characterize the behavior and function of captured CTCs, for example to obtain information on proliferative and invasive properties or, ultimately, tumor re-initiating potential. Although CTCs can be efficiently immunostained with markers reporting phenotype or fate (e.g. apoptosis, proliferation), it has not yet been possible to reliably grow captured CTCs over long periods of time and at single cell level. It is challenging to remove CTCs from a microchip after capture, therefore such analyses should ideally be performed directly on-chip. To address this challenge, we merged CTC capture with three-dimensional (3D) tumor cell culture on the same microfluidic platform. PC3 prostate cancer cells were isolated from spiked blood on a transparent PDMS CTC-chip, encapsulated on-chip in a biomimetic hydrogel matrix (QGel?) that was formed in situ, and their clonal 3D spheroid growth potential was assessed by microscopy over one week in culture. The possibility to clonally expand a subset of captured CTCs in a near-physiological in vitro model adds an important element to the expanding CTC-chip toolbox that ultimately should improve prediction of treatment responses and disease progression. 相似文献
15.
Brenda J. Green Tina Saberi Safaei Adam Mepham Dr. Mahmoud Labib Dr. Reza M. Mohamadi Prof. Shana O. Kelley 《Angewandte Chemie (International ed. in English)》2016,55(4):1252-1265
Over the last decade, significant progress has been made towards the development of approaches that enable the capture of rare circulating tumor cells (CTCs) from the blood of cancer patients, a critical capability for noninvasive tumor profiling. These advances have leveraged new insights in materials chemistry and microfluidics and allowed the capture and enumeration of CTCs with unprecedented sensitivity. However, it has become increasingly clear that simply capturing and counting tumor cells launched into the bloodstream may not provide the information needed to advance our understanding of the biology of these rare cells, or to allow us to better exploit them in medicine. A variety of advances have now emerged demonstrating that more information can be extracted from CTCs with next‐generation devices and materials featuring tailored physical and chemical properties. In this Minireview, the last ten years of work in this area will be discussed, with an emphasis on the groundbreaking work of the last five years, during which the focus has moved beyond the simple capture of CTCs and gravitated towards approaches that enable in‐depth analysis. 相似文献